Global CAR T-Cell Therapy Market: Focus on Product, Mechanism, Application, Target Antigen, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

Report Highlights

Global CAR T-Cell Therapy Market to Grow at a CAGR of 44.79% from 2020-2030

Market Report Coverage - CAR T-Cell Therapy

Market Segmentation

• Therapy Application – Diffuse large B-cell lymphoma (DLBCL), Acute lymphoblastic leukemia (ALL), Multiple myeloma (MM), Chronic lymphocytic leukemia (CLL), Follicular lymphoma (FL), Mantle cell lymphoma (MCL), and other cancers or indications
• Target Antigen – CD19/CD22, BCMA (B-cell maturation antigen), and others target antigens

Regional Segmentation

• North America – U.S., Canada
• Europe – Germany, France, Italy, U.K., Spain, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, South Korea, Australia, and Rest-of-Asia-Pacific (RoAPAC)
• Latin America – Brazil, Mexico, and Rest-of-the-Latin America
• Rest-of-the-World

Growth Drivers

• Rising Number of Patients with Hematologic Cancers
• Dramatic Rise in Global CAR T-Cell Trials
• Landmark Approvals of CAR T-Cell Therapies by the U.S. FDA and the EMA

Market Challenges

• High Treatment Cost of CAR T-Cell Therapy
• Side Effects of CAR T-Cell Therapy

Market Opportunities

• Opportunities for Immunotherapy

Key Companies Profiled

• Amgen, Inc., Autolus Therapeutics plc., Bellicum Pharmaceuticals, Inc., Bluebird Bio Inc., Bristol-Myer Squibb, CARsgen Therapeutics, Ltd., Cartesian Therapeutics, Inc., Cellectis S.A., Celyad Oncology SA, Fortress Biotech, Inc., Janssen Pharmaceuticals, Inc., Kite Pharma, Inc., Legend Biotech Corporation, Novartis AG, and Pfizer, Inc.

Key Questions Answered in this Report:

• What is a CAR T-cell?
• How are CAR T-cells developed?
• What are the various indications targeted using CAR T-cell therapies?
• What are the various CAR T-cell therapies available in the market?
• What are the emerging CAR T-cell therapies for the treatment of hematologic cancers?
• How does the pipeline for the global CAR T-cell therapy market look like?
• What is the current market size and future potential of these CAR T-cell therapies?
• What are the major market drivers, challenges, and opportunities in the global CAR T-cell therapy market?
• What is the mechanism of action of various CAR T-cell therapies available in the market?
• What mechanisms of action and molecules are being trialed the most in pipeline products?
• What are the target antigens in CAR T-cell therapy?
• How does the clinical trial landscape look for the global CAR T-cell therapy market?
• What is the patent landscape of this market? What will be the impact of patent expiry on this market?
• What is the price structure of CAR T-cell products?
• What is the total cost of treating a patient with CAR T-cell therapy?
• What will be the impact of COVID-19 on this market?
• What are the guidelines implemented by different government bodies to regulate the approval of CAR T-cell therapy?
• What are the reimbursement scenario and regulatory structure for CAR T-cell therapy?
• What are the challenges faced by manufacturers in CAR T-cell therapy development?
• What are the key technological developments on which the current industry leaders are spending a major share of their research and development (R&D) investments?
• Which are the leading players currently holding dominating shares in the global CAR T-cell therapy market?
• What are the key strategies incorporated by the players of the global CAR T-cell therapy market to sustain the competition and retain their supremacy?
• What is the current revenue contribution of the global CAR T-cell therapy market (by application type), and how is it expected to evolve in the forecast period?
• What is the current revenue contribution of the global CAR T-cell therapy market (by target antigen), and how is it expected to evolve in the forecast period?
• Which region is expected to contribute the highest revenue to the global CAR T-cell therapy market during the forecast period?